Clinical Management and Targeted Therapy for Common Solid Tumors
This community focuses on the clinical treatment of major solid cancers, specifically investigating how to optimize chemotherapy regimens, manage drug resistance, and integrate targeted and immune-based therapies into patient care.
The research is heavily concentrated on lung, ovarian, bladder, and head and neck cancers, with a strong emphasis on squamous cell and non-small cell subtypes. Recurring themes include the evaluation of platinum-based chemotherapy, particularly cisplatin, and the development of strategies to overcome resistance. The work frequently examines the efficacy and safety of targeted therapies and immune checkpoint inhibitors, often in the context of locally advanced or metastatic disease. Clinical trials, including phase trials and neoadjuvant approaches, form the backbone of the evidence base, alongside detailed case reports and studies on specific tumor biomarkers.
Platinum research accounts for the largest share of this community's output, representing 12.8% of all platinum research tracked, with 18,851 papers in this group. The community publishes most frequently in the Journal of Clinical Oncology, Frontiers in Oncology, and Cancers. Recent work includes trials combining antibody-drug conjugates with immune checkpoint inhibitors for bladder and urothelial cancers, as well as studies on targeted therapies for EGFR-mutated lung cancer and platinum-resistant ovarian cancer.